Please use this identifier to cite or link to this item:
Title: Nicotinic Cholinergic System and COVID-19: Identification of a potentially crucial snake toxin-like sequence in the SARS-CoV-2 Spike glycoprotein.
Other Titles: Νικοτινικό Χολινεργικό Σύστημα και COVID-19: Προσδιορισμός μιας ιδιαίτερα σημαντικής αλληλουχίας με δομή τοξίνης πάνω στην πρωτείνη SPIKE
Authors: Poulas, Konstantinos
Keywords: SARS-CoV-2
Abstract: Smoking is a risk factor for respiratory infections and there is reasonable concern that it may affect COVID-19 susceptibility and severity. Recent studies have focused on the interaction between smoking (and nicotine) and ACE2 expression, suggesting that ACE2 up-regulation could contribute to enhanced viral cell entry. However, case series have shown that there is an unexpectedly low prevalence of smoking among hospitalized COVID-19 cases. Since early April, we were the first to hypothesize that dysfunction of the nicotinic cholinergic system (NCS) may be implicated in the pathophysiology of severe COVID-19 and that nicotine intake could have beneficial effects. We recently reported that many of the clinical manifestations of severe COVID-19 could be explained by dysregulation of the NCS. In this study, we present an amino acid sequence in the receptor binding domain of the SARS-CoV-2 Spike glycoprotein which is homologous to a sequence of the Neurotoxin homolog NL1, one of the snake venom toxins that are known to interact with acetylcholine receptors. We present the 3D structural location of this “toxin-like” sequence on the Spike Glycoprotein and the superposition of the modelled structure of the Neurotoxin homolog NL1 and the SARS-CoV-2 Spike Glycoprotein. These findings suggest that SARS-CoV-2 could potentially interact with acetylcholine receptors causing dysregulation of the NCS and the cholinergic anti-inflammatory pathway. Such interactions may lead to uncontrolled immune response and cytokine storm, which is implicated in the pathophysiology of severe COVID-19.
Appears in Collections:Τμήμα Φαρμακευτικής (Τεχνικές Αναφορές)

Files in This Item:
File Description SizeFormat 
FEBS-J_13MAY_FINAL.docx1.59 MBMicrosoft Word XMLView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.